The number of patients undergoing allogeneic hematopoietic SCT (HSCT) is steadily increasing, and the outcome of this intervention is largely dependent on how well complications in the form of severe infections can adequately be diagnosed and controlled. Established surveillance strategies exist for early detection of CMV and EBV, and there is an ongoing evaluation of the benefit of screening for emerging pathogens such as adenovirus (AdV). 1 As a result of new molecular techniques, knowledge of pathogenic viral infections following transplantation has increased in recent years. As immunosuppressive regimens change and as new viruses are discovered, it is important to continuously update our knowledge about the epidemiology and clinical impact of potentially harmful viruses.
We read with great interest a recently published article by Rahiala et al.
2 in which they describe the occurrence and clinical spectrum of the well-known parvovirus B19 (B19) and two new parvoviruses, parvovirus 4 (PARV4) and human bocavirus (HBoV), in 53 pediatric HSCT recipients. Serum samples collected prior to HSCT as well as 1, 2 and 3 months after the transplantation were analyzed by PCR. Whereas neither PARV4 nor HBoV DNA was found, B19 DNA was detected in one or more consecutive samples in as many as 30% of the children. However, the authors were not able to associate the viremia with known clinical complications, such as (prolonged) cytopenia, in immunocompromised patients. 3, 4 We wish to add our experience in this context. In a prospective longitudinal study of 20 pediatric and 77 adult HSCT recipients, we evaluated the benefit of screening for AdV in parallel to a routine CMV surveillance program. 5 Both plasma and serum samples were collected weekly during the first 9 weeks after HSCT and at followup visits approximately 3, 6, and 12 months later. Whereas the plasma samples were used for detection of AdV DNA, the serum samples were used for detection of B19 DNA by a PCR method. 6 In total, three (3.1%) of the patients, two adults and one child, were B19 DNA positive in sera from one or more of the sampling time points (Table 1) . Although the titers were high in one of the two adults, no clear symptoms of B19 infection were reported in any of the cases. The child had 10 000 copies/mL detected at day 19 post HSCT, but cleared the viremia within 3 weeks. Fever at the beginning of the viremia was the only symptom reported. All three patients had in vivo T-cell depletion in their regimens and the grafts were from matched unrelated donors (peripheral blood). Of the 94 negative patients, a total of 59 (63%, P ¼ 0.55) underwent in vivo T-cell depletion, and 48 (51%, P ¼ 0.24) had grafts from an unrelated donor (66 (70%) from peripheral blood, P ¼ 0.55). Also regarding other patient characteristics, we found no statistically significant differences between B19 DNA-positive andnegative recipients (data not shown). However, with this low number of positive cases there is a great risk of type II errors, and these statistical results should be considered with caution.
The low incidence of B19 in our study is comparable with two other studies on HSCT recipients where incidences of 0% and 1.5% were reported. 7, 8 Furthermore, in a cross-sectional study on adult hematological patients with febrile neutropenia, not subjected to allogeneic HSCT, only six (3.8%) out of 159 had B19 DNA detected and the titers were low. 9 In a similar study on 90 children, a total of two (2.2%) were B19-positive. 10 The incidence of 30% in the study by Rahiala et al.
2 was remarkably higher, but studies on other hematological pediatric patients, non-HSCT though, support their data. 4 Although the reported incidences from studies on allogeneic HCST recipients vary and although there are case reports of severe B19 infections, the clinical impact seems low in this patient category. It is, however, advisable to test for B19 at unexplained cytopenia. 
